ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

ClinicalTrials.gov ID: NCT03768726

Public ClinicalTrials.gov record NCT03768726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 8:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)

Study identification

NCT ID
NCT03768726
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
23 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Ziprasidone Drug

Drug

Eligibility (public fields only)

Age range
10 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 20, 2018
Primary completion
Jul 30, 2020
Completion
Jul 30, 2020
Last update posted
Jun 15, 2021

2018 – 2020

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Medical Research Group of Central Florida Orange City Florida 32763
Inova Clinical Trials and Research Centre Fayetteville Georgia 30214
Attalla Consultants, LLC dba Institute for Behavioral Medicine Smyrna Georgia 30082-2629
Finger Lakes Clinical Research Rochester New York 14618
University of Cincinnati Cincinnati Ohio 45219
Cutting Edge Research Group Oklahoma City Oklahoma 73116
AIM Trials, LLC Plano Texas 75093
Family Psychiatry of the Woodlands The Woodlands Texas 77381
Eastside Therapeutic Resource Inc dba Core Clinical Research Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03768726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03768726 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →